<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006348</url>
  </required_header>
  <id_info>
    <org_study_id>NCCTG-989201</org_study_id>
    <secondary_id>CDR0000068205</secondary_id>
    <secondary_id>NCI-P00-0168</secondary_id>
    <nct_id>NCT00006348</nct_id>
  </id_info>
  <brief_title>Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment</brief_title>
  <official_title>Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and
      vomiting in patients with advanced cancer.

      PURPOSE: This randomized phase III trial is studying how well ondansetron works compared to a
      placebo in treating patients with advanced cancer and chronic nausea and vomiting that is not
      caused by cancer therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the antiemetic effect of ondansetron vs placebo in patients with
      advanced cancer who suffer from chronic nausea and emesis that is not due to antineoplastic
      therapy (i.e., chemotherapy, radiotherapy, immunotherapy, biologic therapy). II. Determine
      the toxicity of ondansetron in these patients. III. Evaluate the use of other concurrent
      antiemetics in these patients when treated with this regimen.

      OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study. Patients
      are stratified according to abdominal carcinomatosis (yes vs no), renal insufficiency
      (creatinine less than 2.0 mg/dL vs creatinine at least 2.0 mg/dL), type of cancer (brain vs
      gastrointestinal vs other), and narcotic use (yes vs no). Patients are randomized to one of
      two treatment arms. Arm I: Patients receive oral ondansetron twice daily on days 1-7 and oral
      placebo twice daily on days 8-14 in the absence of unacceptable toxicity. Arm II: Patients
      receive oral placebo twice daily on days 1-7 and oral ondansetron twice daily on days 8-14 in
      the absence of unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 100 patients (50 per arm) will be accrued for this study within
      1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <completion_date type="Actual">September 2001</completion_date>
  <primary_completion_date type="Actual">September 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Nausea and Vomiting</condition>
  <condition>Precancerous Condition</condition>
  <condition>Small Intestine Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm 1: ondansetron + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral ondansetron twice daily on days 1-7 and oral placebo twice daily on days 8-14 in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: ondansetron + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral placebo twice daily on days 1-7 and oral ondansetron twice daily on days 8-14 in the absence of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
    <arm_group_label>Arm 1: ondansetron + placebo</arm_group_label>
    <arm_group_label>Arm 2: ondansetron + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Arm 1: ondansetron + placebo</arm_group_label>
    <arm_group_label>Arm 2: ondansetron + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Diagnosis of incurable cancer with chronic nausea and vomiting
        lasting at least 1 week that is not due to antineoplastic therapy (i.e., chemotherapy,
        radiotherapy, immunotherapy, biologic therapy) Nausea not adequately controlled by standard
        antiemetics

        PATIENT CHARACTERISTICS: Cardiovascular: No uncontrolled hypertension Other: Not pregnant
        or nursing Able to take oral medication (feeding tube allowed) Able to swallow own saliva
        No prior phenylketonuria No known allergy or intolerance to 5-HT3 receptor antagonists No
        bowel obstruction

        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See
        Disease Characteristics At least 2 weeks since prior cytotoxic systemic therapy No
        concurrent cytotoxic systemic therapy Endocrine therapy: Not specified Radiotherapy: See
        Disease Characteristics At least 2 weeks since prior radiotherapy to gastrointestinal tract
        No concurrent radiotherapy to gastrointestinal tract Surgery: Not specified Other: At least
        2 weeks since prior 5-HT3 receptor antagonists (i.e., dolasetron, granisetron, or
        ondansetron) No other concurrent 5-HT3 receptor antagonists Other concurrent antiemetics
        allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven R. Alberts, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Scottsdale Oncology Program</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Iowa Oncology Research Association</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309-1016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siouxland Hematology-Oncology</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101-1733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-3882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Missouri Valley Cancer Consortium</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medcenter One Health System</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altru Health Systems</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Toledo Community Hospital Oncology Program</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623-3456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid City Regional Hospital</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Sioux Community Cancer Consortium</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105-1080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2000</study_first_submitted>
  <study_first_submitted_qc>March 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2004</study_first_posted>
  <last_update_submitted>July 1, 2016</last_update_submitted>
  <last_update_submitted_qc>July 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>monoclonal gammopathy of undetermined significance</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>isolated plasmacytoma of bone</keyword>
  <keyword>extramedullary plasmacytoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>Waldenstr√∂m macroglobulinemia</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>meningeal chronic myelogenous leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>untreated childhood acute myeloid leukemia and other myeloid malignancies</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>untreated hairy cell leukemia</keyword>
  <keyword>progressive hairy cell leukemia, initial treatment</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>nausea and vomiting</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related primary CNS lymphoma</keyword>
  <keyword>primary systemic amyloidosis</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

